- Home
- FT vs RAPT Comparison
FT vs RAPT Comparison
Compare FT & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FT
- RAPT
- Stock Information
- Founded
- FT 1988
- RAPT 2015
- Country
- FT United States
- RAPT United States
- Employees
- FT N/A
- RAPT N/A
- Industry
- FT Trusts Except Educational Religious and Charitable
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- FT Finance
- RAPT Health Care
- Exchange
- FT Nasdaq
- RAPT Nasdaq
- Market Cap
- FT 192.5M
- RAPT 194.2M
- IPO Year
- FT N/A
- RAPT 2019
- Fundamental
- Price
- FT $7.90
- RAPT $11.32
- Analyst Decision
- FT
- RAPT Buy
- Analyst Count
- FT 0
- RAPT 5
- Target Price
- FT N/A
- RAPT $33.60
- AVG Volume (30 Days)
- FT 63.0K
- RAPT 103.2K
- Earning Date
- FT 01-01-0001
- RAPT 08-07-2025
- Dividend Yield
- FT 7.85%
- RAPT N/A
- EPS Growth
- FT N/A
- RAPT N/A
- EPS
- FT N/A
- RAPT N/A
- Revenue
- FT N/A
- RAPT N/A
- Revenue This Year
- FT N/A
- RAPT N/A
- Revenue Next Year
- FT N/A
- RAPT N/A
- P/E Ratio
- FT N/A
- RAPT N/A
- Revenue Growth
- FT N/A
- RAPT N/A
- 52 Week Low
- FT $5.97
- RAPT $5.67
- 52 Week High
- FT $7.23
- RAPT $26.56
- Technical
- Relative Strength Index (RSI)
- FT 53.13
- RAPT 54.68
- Support Level
- FT $7.93
- RAPT $10.06
- Resistance Level
- FT $8.00
- RAPT $12.25
- Average True Range (ATR)
- FT 0.09
- RAPT 1.02
- MACD
- FT -0.02
- RAPT -0.05
- Stochastic Oscillator
- FT 34.62
- RAPT 73.29
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company. Its primary investment objective is to provide high, current income consistent with the preservation of capital. Its secondary objective is the growth of income through dividend increases and capital appreciation. The fund invests in two asset classes being the high yield bonds and utility stocks.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.